Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Drug:  ALK inhibitor X-396
Find trials that include:  Any drugs shown
Results 1-2 of 2 for your search:
Start Over
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: X396-CLI-301, NCI-2016-00877, NCT02767804
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: X396-CLI-101, NCI-2012-01257, NCT01625234
Start Over